Genzyme/Schering Gear For Campath Phase III MS Trial Despite Phase II Halt
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genzyme and Schering AG plan to initiate a Campath Phase III trial for multiple sclerosis despite stopping the Phase II program due to safety concerns